Affiliation:
1. 1UPMC Hillman Cancer Center and the University of Pittsburgh, Pittsburgh, Pennsylvania.
Abstract
Summary
Combination immune-checkpoint inhibition with chemotherapy is a clinical standard, yet concurrent administration may limit the full benefit of immunotherapy by blunting the proliferation and differentiation of CD8 T cells. Identifying patients in whom sequential chemo-immunotherapy or immunotherapy alone is feasible should be a priority to optimize long-term outcomes.
See related article by Mariniello et al., p. 1833
Funder
National Institutes of Health
Publisher
American Association for Cancer Research (AACR)
Reference20 articles.
1. Platinum-based chemotherapy attenuates the effector response of CD8 T cells to concomitant PD-1 blockade;Mariniello;Clin Cancer Res,2024
2. Immunogenic cell death in cancer and infectious disease;Galluzzi;Nat Rev Immunol,2017
3. Chemotherapy combines effectively with anti-PD-L1 treatment and can augment antitumor responses;Cubas;J Immunol,2018
4. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC;Antonia;N Engl J Med,2018